Beiersdorf demonstrated outstanding growth in fiscal year 2024, again achieving record sales and solid results in all its business segments. Group sales amounted to a record EUR 9.9 billion, with organic growth of 6.5%. Despite major brand investments, the result increased to 1.4 billion euros, improving the EBIT margin to 13.9%.

Vincent Warnery, CEO of Beiersdorf, commented that, for the second year in a row, Beiersdorf is the best-performing global skin care company. “We are continuing our outstanding development of the past years in 2024, achieving another sales record, even in a challenging market environment.” he stressed.

The results, described as historic, are the result of a strategy that focuses on strong brands, delivers breakthrough innovations and expands our markets, categories and channels. “With the Group’s 2025 forecast, we believe we will outperform the market again this year,” Warney added.

The traditional Nivea can is still one of the flagship products, but Beiersdorf’s diversification is undeniable.

All key product categories showed significant growth in 2024. The LUMINOUS630 line, with the patented anti-stain ingredient Thiamidol®, achieved an impressive 34% organic growth.

The Derma business continued its successful trend, achieving double-digit organic sales growth of 10.6%, reaching total sales of €1.4 billion. Growth was driven mainly by strong innovations. Eucerin became the second billion-euro brand in Beiersdorf’s Consumer portfolio after NIVEA. The Eucerin Face category experienced significant growth, driven by the expansion of the Thiamidol® line in the anti-pigment segment. In 2024, Beiersdorf launched a new epigenetic serum with the anti-aging innovation Epicelline® in the Eucerin product line, marking the largest launch in the history of the Derma business. Other milestones included the successful introduction of Eucerin Face in the United States and the launch of Eucerin in India, a promising market with great growth potential in the skin care sector.

Health Care reported organic sales growth of 6.1%, reaching 282 million euros.